Circulating Tumor DNA to Predict Surgical Outcome after Neoadjuvant Chemoradiation for Borderline Resectable/Locally Advanced Pancreatic Cancer
Susan G. R. McDuff, Theodore S. Hong(Massachusetts General Hospital), Colin D. Weekes(Massachusetts General Hospital), Jamyia Clark(Massachusetts General Hospital), Ryan B. Corcoran(Massachusetts General Hospital), J.Y. Wo(Harvard University), Mehlika Hazar-Rethinam(Massachusetts General Hospital), C. Fernandez-del Casti(Massachusetts General Hospital), Love Goyal(The Christie NHS Foundation Trust), Keith D. Lillemoe(Harvard University), An Zhu(Fujian Medical University), Jackie Allen(Massachusetts General Hospital), Jochen K. Lennerz(Addgene), Emily Van Seventer(Massachusetts General Hospital), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Brandon Nadres(Massachusetts General Hospital), C.R. Ferrone(Massachusetts General Hospital), Huili Zheng(Massachusetts General Hospital), D. P. Ryan(Massachusetts General Hospital), Aparna Parikh(Massachusetts General Hospital)
International Journal of Radiation Oncology*Biology*Physics
October 19, 2018
Cited by 0
Related Papers
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
|Nature Communications|2017|999
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914